AZD9550

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 DiabetesWeight LossObesity & OverweightHepatic Impairment

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

1

AZD9550

AstraZeneca

Phase 2

62

Jardiance

Boehringer Ingelheim

Preclinical

313

NOVOLIN R

Novo Nordisk

Preclinical

54

Cysteine Hydrochloride

Novartis

Preclinical

15

Glargine

Eli Lilly

Preclinical

86

Aurlumyn

BBTG International Inc.

Preclinical

17

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

18

Forxiga

AstraZeneca

Preclinical

39

Lovaza

AstraZeneca

Preclinical

110

Acipimox

Boehringer Ingelheim

Preclinical

2Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Overweight1 trial

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Recruiting·AstraZeneca·Phase 1·NCT07013643·75 enrolled

Single Ascending Dose1 trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Completed·AstraZeneca·Phase 1·NCT05848440·48 enrolled

Weight loss1 trial

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Active, not recruiting·AstraZeneca·Phase 2·NCT06862791·377 enrolled

Hepatic Impairment1 trial

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

Recruiting·AstraZeneca·Phase 1·NCT07546760·28 enrolled

Obesity & Overweight1 trial

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

Active, not recruiting·AstraZeneca·Phase 2·NCT07017179·14 enrolled

1 more indication

Overweight and Obesity1 trial

A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity and Overweight With or Without Type 2 Diabetes Mellitus

Active, not recruiting·AstraZeneca·Preclinical·NCT06151964·166 enrolled

Details

Drug Info

Related News